JP2001518512A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001518512A5 JP2001518512A5 JP2000514658A JP2000514658A JP2001518512A5 JP 2001518512 A5 JP2001518512 A5 JP 2001518512A5 JP 2000514658 A JP2000514658 A JP 2000514658A JP 2000514658 A JP2000514658 A JP 2000514658A JP 2001518512 A5 JP2001518512 A5 JP 2001518512A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- disease
- cell
- hepatitis
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6095397P | 1997-10-06 | 1997-10-06 | |
| US60/060,953 | 1997-10-06 | ||
| PCT/IB1998/001676 WO1999017787A2 (en) | 1997-10-06 | 1998-10-06 | Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001518512A JP2001518512A (ja) | 2001-10-16 |
| JP2001518512A5 true JP2001518512A5 (enExample) | 2006-01-05 |
| JP4369615B2 JP4369615B2 (ja) | 2009-11-25 |
Family
ID=22032774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000514658A Expired - Fee Related JP4369615B2 (ja) | 1997-10-06 | 1998-10-06 | 抗原特異的免疫応答を抑制するための化学的に安定化された亜塩素酸塩溶液の使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20050129784A1 (enExample) |
| EP (1) | EP1021196B1 (enExample) |
| JP (1) | JP4369615B2 (enExample) |
| CN (1) | CN1152691C (enExample) |
| AT (1) | ATE258799T1 (enExample) |
| AU (1) | AU754928B2 (enExample) |
| CA (1) | CA2306273A1 (enExample) |
| DE (1) | DE69821506T2 (enExample) |
| DK (1) | DK1021196T3 (enExample) |
| ES (1) | ES2217582T3 (enExample) |
| PT (1) | PT1021196E (enExample) |
| WO (1) | WO1999017787A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11813234B2 (en) | 2015-08-20 | 2023-11-14 | Oxo Translational Science Gmbh | Use of chlorite to treat red blood cell diseases and indications mediated thereby |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL148189A0 (en) * | 1999-08-18 | 2002-09-12 | Oxo Chemie Ag | Chemically-stabilized chlorite solutions for treating cancer and other diseases |
| AU2011205095B2 (en) * | 2004-02-03 | 2014-07-03 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| US7105183B2 (en) | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| US8067035B2 (en) | 2005-12-22 | 2011-11-29 | Neuraltus Pharmaceuticals, Inc. | Chlorite formulations, and methods of preparation and use thereof |
| WO2008145376A1 (en) * | 2007-06-01 | 2008-12-04 | Dimethaid Ag | Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis |
| EA201290041A1 (ru) * | 2009-08-06 | 2012-07-30 | Ньюралтус Фармасьютикалс, Инк. | Лечение расстройств, связанных с макрофагами |
| US9266957B2 (en) | 2009-11-10 | 2016-02-23 | Mayo Foundation For Medical Education And Research | Methods and materials for treating renal cell carcinoma and glioblastoma multiforme |
| RU2014130080A (ru) | 2011-12-22 | 2016-02-10 | Нуво Рисерч Гмбх | Липосомальные композиции хлоритов или хлоратов |
| CN104519890A (zh) * | 2012-01-19 | 2015-04-15 | Ibt美国公司 | 四氯十氧(tcdo)的治疗应用 |
| WO2014078272A1 (en) | 2012-11-13 | 2014-05-22 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing immune system profiles |
| US10094835B2 (en) | 2013-05-09 | 2018-10-09 | Mayo Foundation For Medical Education And Research | Treating patients based on immune subtypes |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4574084A (en) * | 1983-02-25 | 1986-03-04 | Peter Berger | Process for the preparation of a modified aqueous chlorite solution, the solution prepared by this process and the use thereof |
| DE3515745A1 (de) * | 1985-05-02 | 1986-11-06 | Oxo Chemie GmbH, 6900 Heidelberg | Waessrige chloritmatrix-loesung |
| DE3515749A1 (de) * | 1985-05-02 | 1986-11-06 | Oxo Chemie GmbH, 6900 Heidelberg | Verwendung einer stabilisierten chloritmatrixloesung bei infektioesen zustaenden |
| US4851222A (en) * | 1988-01-27 | 1989-07-25 | Oxo Chemie Gmbh | Method of promoting regeneration of bone marrow |
| US4956184A (en) * | 1988-05-06 | 1990-09-11 | Alcide Corporation | Topical treatment of genital herpes lesions |
| DE4208828A1 (de) * | 1992-03-19 | 1993-09-23 | Oxo Chemie Gmbh | Verwendung einer chemisch stabilisierten chloritmatrix zur herstellung von arzneimitteln zur behandlung von hiv-infektionen |
| US5830511A (en) * | 1992-06-25 | 1998-11-03 | Bioxy Inc. | Therapeutic, production and immunostimulatory uses of biocidal compositions |
| US5877222A (en) * | 1996-07-19 | 1999-03-02 | The Regents Of The University Of California | Method for treating aids-associated dementia |
| WO2008145376A1 (en) * | 2007-06-01 | 2008-12-04 | Dimethaid Ag | Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis |
-
1998
- 1998-10-06 AU AU93642/98A patent/AU754928B2/en not_active Ceased
- 1998-10-06 EP EP98946681A patent/EP1021196B1/en not_active Expired - Lifetime
- 1998-10-06 AT AT98946681T patent/ATE258799T1/de active
- 1998-10-06 JP JP2000514658A patent/JP4369615B2/ja not_active Expired - Fee Related
- 1998-10-06 PT PT98946681T patent/PT1021196E/pt unknown
- 1998-10-06 CN CNB988118858A patent/CN1152691C/zh not_active Expired - Fee Related
- 1998-10-06 WO PCT/IB1998/001676 patent/WO1999017787A2/en not_active Ceased
- 1998-10-06 ES ES98946681T patent/ES2217582T3/es not_active Expired - Lifetime
- 1998-10-06 DE DE69821506T patent/DE69821506T2/de not_active Expired - Lifetime
- 1998-10-06 DK DK98946681T patent/DK1021196T3/da active
- 1998-10-06 CA CA002306273A patent/CA2306273A1/en not_active Abandoned
-
2004
- 2004-07-22 US US10/895,941 patent/US20050129784A1/en not_active Abandoned
-
2008
- 2008-06-04 US US12/132,761 patent/US20090004295A1/en not_active Abandoned
-
2010
- 2010-09-30 US US12/894,618 patent/US20110076344A1/en not_active Abandoned
-
2012
- 2012-02-06 US US13/366,595 patent/US20120141514A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11813234B2 (en) | 2015-08-20 | 2023-11-14 | Oxo Translational Science Gmbh | Use of chlorite to treat red blood cell diseases and indications mediated thereby |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Calich et al. | Cytokines produced by susceptible and resistant mice in the course of Paracoccidioides brasiliensis infection | |
| Bentwich et al. | Immune activation is a dominant factor in the pathogenesis of African AIDS | |
| Noble et al. | IFN-γ and IL-4 regulate the growth and differentiation of CD8+ T cells into subpopulations with distinct cytokine profiles | |
| Miescher | Systemic lupus erythematosus | |
| Nishikawa et al. | In the absence of endogenous gamma interferon, mice acutely infected with Neospora caninum succumb to a lethal immune response characterized by inactivation of peritoneal macrophages | |
| Mege et al. | The two faces of interleukin 10 in human infectious diseases | |
| Lapinet et al. | Gene expression and production of tumor necrosis factor alpha, interleukin-1β (IL-1β), IL-8, macrophage inflammatory protein 1α (MIP-1α), MIP-1β, and gamma interferon-inducible protein 10 by human neutrophils stimulated with group B meningococcal outer membrane vesicles | |
| Cohn et al. | T helper 1 cells and interferon γ regulate allergic airway inflammation and mucus production | |
| Olivares-Villagómez et al. | Repertoire requirements of CD4+ T cells that prevent spontaneous autoimmune encephalomyelitis | |
| Kemeny et al. | CD8+ T cell subsets and chronic obstructive pulmonary disease | |
| Löhning et al. | T1/ST2 expression is enhanced on CD4+ T cells from schistosome egg-induced granulomas: analysis of Th cell cytokine coexpression ex vivo | |
| Jordan et al. | Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin | |
| Jensen et al. | Fas (CD95)-dependent cell-mediated immunity to Listeria monocytogenes | |
| Sobel et al. | Gamma interferon paradoxically inhibits the development of diabetes in the NOD mouse | |
| Ring et al. | Interferon-γ Is Necessary for Initiating the Acute Rejection of Major Histocompatibility Complex Class Ii-Disparate Skin ALLOGRAFTS1 | |
| Julia et al. | CD4+ T cells which react to the Leishmania major LACK antigen rapidly secrete interleukin-4 and are detrimental to the host in resistant B10. D2 mice | |
| Correia-Neves et al. | Immunological hyporesponsiveness in tuberculosis: The role of mycobacterial glycolipids | |
| JP2003534281A5 (enExample) | ||
| Huber et al. | γδ+ T cells regulate major histocompatibility complex class II (IA and IE)-dependent susceptibility to coxsackievirus B3-induced autoimmune myocarditis | |
| Grisotto et al. | Most parasite‐specific CD8+ cells in Trypanosoma cruzi‐infected chronic mice are down‐regulated for T‐cell receptor‐αβ and CD8 molecules | |
| Sheridan et al. | Interleukin-11 attenuates pulmonary inflammation and vasomotor dysfunction in endotoxin-induced lung injury | |
| Ohga et al. | Dominant expression of interleukin 10 but not interferon γ in CD4–CD8–αβT cells of autoimmune lymphoproliferative syndrome | |
| Jacob | Studies on the role of tumor necrosis factor inmurine and human autoimmunity | |
| Bourreau et al. | IFN‐γ‐producing CD45RA+ CD8+ and IL‐10‐producing CD45RA–CD4+ T cells generated in response to LACK in naive subjects never exposed to Leishmania | |
| Franco et al. | Liver-derived T cell clones in autoimmune chronic active hepatitis: accessory cell function of hepatocytes expressing class II major histocompatibility complex molecules |